Free Trial

Exact Sciences (EXAS) Stock Price, News & Analysis

Exact Sciences logo
$59.40 +3.29 (+5.86%)
(As of 12/20/2024 05:51 PM ET)

About Exact Sciences Stock (NASDAQ:EXAS)

Key Stats

Today's Range
$55.98
$59.70
50-Day Range
$49.33
$71.93
52-Week Range
$40.62
$79.62
Volume
3.27 million shs
Average Volume
2.62 million shs
Market Capitalization
$10.99 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$72.94
Consensus Rating
Moderate Buy

Company Overview

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Exact Sciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
91st Percentile Overall Score

EXAS MarketRank™: 

Exact Sciences scored higher than 91% of companies evaluated by MarketBeat, and ranked 102nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Exact Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 17 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Exact Sciences has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Exact Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Exact Sciences are expected to grow in the coming year, from ($1.13) to ($0.28) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Exact Sciences is -50.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Exact Sciences is -50.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Exact Sciences has a P/B Ratio of 3.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.39% of the outstanding shares of Exact Sciences have been sold short.
  • Short Interest Ratio / Days to Cover

    Exact Sciences has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Exact Sciences has recently decreased by 14.52%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Exact Sciences does not currently pay a dividend.

  • Dividend Growth

    Exact Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.39% of the outstanding shares of Exact Sciences have been sold short.
  • Short Interest Ratio / Days to Cover

    Exact Sciences has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Exact Sciences has recently decreased by 14.52%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Exact Sciences has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Exact Sciences this week, compared to 9 articles on an average week.
  • Search Interest

    Only 6 people have searched for EXAS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Exact Sciences insiders have bought 1,439.79% more of their company's stock than they have sold. Specifically, they have bought $1,001,325.00 in company stock and sold $65,030.00 in company stock.

  • Percentage Held by Insiders

    Only 1.36% of the stock of Exact Sciences is held by insiders.

  • Percentage Held by Institutions

    88.82% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Exact Sciences' insider trading history.
Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

EXAS Stock News Headlines

Brokerages Set Exact Sciences Co. (NASDAQ:EXAS) PT at $72.94
Exact Sciences: Profitability Remains Elusive
Rare "crisis signal" triggers for third time in U.S. market
A rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the market crashed 78% (the dot-com bust) and 89% (the Great Depression). Today, according to one of America's leading experts (who has predicted nearly every financial crisis of the last 25 years), what's coming next could soon crash the market by 50% or more, and keep it down for 10, 20, or even 30 years.
Exact Sciences (EXAS) Gets a Buy from TD Cowen
See More Headlines

EXAS Stock Analysis - Frequently Asked Questions

Exact Sciences' stock was trading at $73.98 at the beginning of 2024. Since then, EXAS shares have decreased by 19.7% and is now trading at $59.40.
View the best growth stocks for 2024 here
.

Exact Sciences Co. (NASDAQ:EXAS) issued its quarterly earnings results on Tuesday, November, 5th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.01. The business's revenue for the quarter was up 12.8% compared to the same quarter last year.

Exact Sciences subsidiaries include these companies: Ashion Analytics, Thrive Earlier Detection Corporation, Base Genomics Limited, Paradigm Diagnostics Inc., Viomics Inc., Biomatrica Inc., Armune BioScience, and others.

Top institutional shareholders of Exact Sciences include Geode Capital Management LLC (1.68%), Champlain Investment Partners LLC (1.35%), Holocene Advisors LP (1.01%) and Bellevue Group AG (0.78%). Insiders that own company stock include Kevin T Conroy, Sarah Condella, Katherine S Zanotti, James Edward Doyle, Everett Cunningham, D Scott Coward, Daniel J Levangie, Jacob A Orville, Brian Baranick, Jeffrey Thomas Elliott and James Herriott.
View institutional ownership trends
.

Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Exact Sciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Adobe (ADBE) and Arista Networks (ANET).

Company Calendar

Last Earnings
11/05/2024
Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:EXAS
CUSIP
30063P10
Employees
6,600
Year Founded
1995

Price Target and Rating

Average Stock Price Target
$72.94
High Stock Price Target
$90.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+22.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.94
Research Coverage
18 Analysts

Profitability

Net Income
$-204,150,000.00
Pretax Margin
-7.82%

Debt

Sales & Book Value

Annual Sales
$2.69 billion
Cash Flow
$0.02 per share
Book Value
$17.39 per share

Miscellaneous

Free Float
182,559,000
Market Cap
$10.99 billion
Optionable
Optionable
Beta
1.24

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:EXAS) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners